Clinical trial NCT00003225: Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer
Official title: Phase I/II Trial to Evaluate Ethyol as a Protective Agent for Irinotecan (CPT-11) Toxicities in Patients With Advanced Colorectal Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Colorectal Cancer
Keywords: stage IV colon cancer
stage IV rectal cancer
recurrent colon cancer
recurrent rectal cancer
Lead sponsor: Jonsson Comprehensive Cancer Center
Sponsor class: OTHER
Collaborators: name: ALZA
First posted: 2004-07-21
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I/II trial to study the effectiveness of amifostine plus irinotecan in treating patients with metastatic colorectal cancer.

Detailed description: OBJECTIVES: I. Assess the toxicity profile of irinotecan and amifostine when administered together in patients with metastatic colorectal cancer. II. Assess the total dose of irinotecan received per 6 week course in these patients. III. Determine the incidence of irinotecan-induced leukopenia, neutropenia, and diarrhea in these patients. V. Determine the response rate for this patient population.

OUTLINE: This is an open label study. Amifostine is administered by 10 minute IV infusions. Irinotecan is administered by IV infusions 15 minutes after completion of amifostine. Treatment is repeated every 2 weeks for 6 weeks. This 6 week course is repeated in the absence of disease progression. Treatment may be delayed up to 2 weeks after a course to allow for recovery from toxic effects. Patients are followed at the end of study and at 30 days after study.

PROJECTED ACCRUAL: There will be 25-30 patients accrued into this study.

Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* ECOG 0-2
* Life expectancy of at least 12 weeks
* Pathologically confirmed diagnosis of metastatic colorectal cancer
* Measureable disease
* Have not received therapy for cancer within 4 weeks of enrollment on study
* Prior radiation therapy to the pelvis for treatment of colorectal cancer is allowed. Radiation therapy delivered elsewhere is allowed as long as the patient has been off treatment for at least six weeks and measurable lesions are present outside the radiation field
* Pretreatment granulocyte count of \> 1500/mm3, hemoglobin \> 9.0 g/dL (without transfusion), and platelet count of \> 100,000/um
* Serum creatinine \< 2.0 mg/dL
* Adequate hepatic function as documented by a serum bilirubin \< 2.0 mg/dL regardless of whether patients have liver involvement secondary to tumor. AST must be \< 3x the upper limit of normal unless the liver is involved with tumor, in which case the AST must be \< 5x institutional upper limit of normal

Exclusion Criteria:

* Prior therapy with Irinotecan
* Patients with any active or uncontrolled infection
* Patients with psychiatric disorders that would interfere with consent or follow-up
* Patients with a history of myocardial infarction within the previous six months, congestive heart failure, or cerebrovascular disease
* History of prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least five years
* Presence of clinically apparent central nervous system metastases or carcinomatous meningitis
* Patients with uncontrolled diabetes mellitus
* Any other sever concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study
* Patients unable to stop taking antihypertensive medication 24 hour prior to administration of Ethyol (off x 1 day)

Primary outcomes:
measure: To assess the toxicity profile of Irinotecan and Ethyol when administered together on this schedule.
timeFrame: 12 weeks
Secondary outcomes:
measure: To assess the total dose of Irinotecan received per 6 week cycle
timeFrame: 6 weeks
measure: To determine incidence of Irinotecan-induced leukopenia and neutropenia
timeFrame: 12 weeks
measure: To determine the incidence of Irinotecan-induced diarrhea
timeFrame: 12 weeks
measure: To determine the response rate for patients with metastatic colorectal carcinoma receiving Irinotecan and Ethyol on this dosing schedule (as measured by time response, duration of response time to progression, time of treatment failure survival).
timeFrame: 12 weeks
measure: To determine the clinical benefit of intravenous Irinotecan and Ethyol in patients with colorectal cancer, as measured by performance status, analgesic consumption, quality of life and survival.
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Jonsson Comprehensive Cancer Center, UCLA
state: California
city: Rancho Cucamonga
country: United States
facility: Wilshire Oncology Medical Group, Inc.
state: California
Study officials:
affiliation: Jonsson Comprehensive Cancer Center
name: Diane Prager, MD
role: STUDY_CHAIR
References: